vs
Side-by-side financial comparison of INSTEEL INDUSTRIES INC (IIIN) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
INSTEEL INDUSTRIES INC is the larger business by last-quarter revenue ($159.9M vs $129.7M, roughly 1.2× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 23.3%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 12.0%).
Insteel Industries Inc is a leading U.S. manufacturer of steel reinforcing products including welded wire reinforcement and steel fibers. It primarily serves non-residential construction, infrastructure, and precast concrete segments across North America, delivering high-performance reinforcement solutions for various construction projects.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
IIIN vs TVTX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $159.9M | $129.7M |
| Net Profit | $7.6M | — |
| Gross Margin | 11.3% | 98.0% |
| Operating Margin | 6.0% | -25.0% |
| Net Margin | 4.7% | — |
| Revenue YoY | 23.3% | 73.4% |
| Net Profit YoY | 602.4% | — |
| EPS (diluted) | $0.39 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $159.9M | $129.7M | ||
| Q3 25 | $177.4M | $164.9M | ||
| Q2 25 | $179.9M | $114.4M | ||
| Q1 25 | $160.7M | $81.7M | ||
| Q4 24 | $129.7M | $74.8M | ||
| Q3 24 | $134.3M | $62.9M | ||
| Q2 24 | $145.8M | $54.1M | ||
| Q1 24 | $127.4M | $41.4M |
| Q4 25 | $7.6M | — | ||
| Q3 25 | $14.6M | $25.7M | ||
| Q2 25 | $15.2M | $-12.8M | ||
| Q1 25 | $10.2M | $-41.2M | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $4.7M | $-54.8M | ||
| Q2 24 | $6.6M | $-70.4M | ||
| Q1 24 | $6.9M | $-136.1M |
| Q4 25 | 11.3% | 98.0% | ||
| Q3 25 | 16.1% | 99.0% | ||
| Q2 25 | 17.1% | 98.7% | ||
| Q1 25 | 15.3% | 94.3% | ||
| Q4 24 | 7.3% | 96.6% | ||
| Q3 24 | 9.1% | 97.4% | ||
| Q2 24 | 10.6% | 96.2% | ||
| Q1 24 | 12.3% | 96.4% |
| Q4 25 | 6.0% | -25.0% | ||
| Q3 25 | 10.8% | 15.1% | ||
| Q2 25 | 11.0% | -11.1% | ||
| Q1 25 | 8.3% | -52.2% | ||
| Q4 24 | 1.1% | -81.2% | ||
| Q3 24 | 4.5% | -89.3% | ||
| Q2 24 | 6.0% | -125.1% | ||
| Q1 24 | 7.0% | -336.5% |
| Q4 25 | 4.7% | — | ||
| Q3 25 | 8.2% | 15.6% | ||
| Q2 25 | 8.4% | -11.1% | ||
| Q1 25 | 6.4% | -50.4% | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 3.5% | -87.1% | ||
| Q2 24 | 4.5% | -130.1% | ||
| Q1 24 | 5.4% | -328.9% |
| Q4 25 | $0.39 | $0.04 | ||
| Q3 25 | $0.74 | $0.28 | ||
| Q2 25 | $0.78 | $-0.14 | ||
| Q1 25 | $0.52 | $-0.47 | ||
| Q4 24 | $0.06 | $-0.71 | ||
| Q3 24 | $0.24 | $-0.70 | ||
| Q2 24 | $0.34 | $-0.91 | ||
| Q1 24 | $0.35 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $15.6M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $358.8M | $114.8M |
| Total Assets | $456.1M | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.6M | $93.0M | ||
| Q3 25 | $38.6M | $110.9M | ||
| Q2 25 | $53.7M | $75.2M | ||
| Q1 25 | $28.4M | $61.9M | ||
| Q4 24 | $36.0M | $58.5M | ||
| Q3 24 | $111.5M | $36.4M | ||
| Q2 24 | $97.7M | $32.3M | ||
| Q1 24 | $83.9M | $43.3M |
| Q4 25 | $358.8M | $114.8M | ||
| Q3 25 | $371.5M | $73.6M | ||
| Q2 25 | $356.2M | $32.7M | ||
| Q1 25 | $341.4M | $32.8M | ||
| Q4 24 | $331.6M | $59.1M | ||
| Q3 24 | $350.9M | $-30.5M | ||
| Q2 24 | $346.0M | $15.1M | ||
| Q1 24 | $340.6M | $74.1M |
| Q4 25 | $456.1M | $605.2M | ||
| Q3 25 | $462.6M | $538.6M | ||
| Q2 25 | $471.9M | $555.3M | ||
| Q1 25 | $421.9M | $548.8M | ||
| Q4 24 | $404.7M | $594.1M | ||
| Q3 24 | $422.6M | $504.4M | ||
| Q2 24 | $414.6M | $551.1M | ||
| Q1 24 | $397.2M | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-701.0K | $60.7M |
| Free Cash FlowOCF − Capex | $-2.2M | — |
| FCF MarginFCF / Revenue | -1.4% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | -0.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $439.0K | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-701.0K | $60.7M | ||
| Q3 25 | $-17.0M | $14.3M | ||
| Q2 25 | $28.5M | $5.0M | ||
| Q1 25 | $-3.3M | $-42.2M | ||
| Q4 24 | $19.0M | $-35.7M | ||
| Q3 24 | $16.2M | $-42.5M | ||
| Q2 24 | $18.8M | $-40.2M | ||
| Q1 24 | $1.4M | $-119.0M |
| Q4 25 | $-2.2M | — | ||
| Q3 25 | $-18.7M | $14.2M | ||
| Q2 25 | $26.9M | — | ||
| Q1 25 | $-5.5M | — | ||
| Q4 24 | $16.3M | — | ||
| Q3 24 | $14.5M | — | ||
| Q2 24 | $15.5M | $-40.3M | ||
| Q1 24 | $-580.0K | — |
| Q4 25 | -1.4% | — | ||
| Q3 25 | -10.6% | 8.6% | ||
| Q2 25 | 15.0% | — | ||
| Q1 25 | -3.5% | — | ||
| Q4 24 | 12.6% | — | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 10.7% | -74.5% | ||
| Q1 24 | -0.5% | — |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 1.0% | 0.1% | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 1.3% | 0.0% | ||
| Q2 24 | 2.2% | 0.2% | ||
| Q1 24 | 1.5% | 0.0% |
| Q4 25 | -0.09× | — | ||
| Q3 25 | -1.17× | 0.56× | ||
| Q2 25 | 1.88× | — | ||
| Q1 25 | -0.32× | — | ||
| Q4 24 | 17.56× | — | ||
| Q3 24 | 3.48× | — | ||
| Q2 24 | 2.86× | — | ||
| Q1 24 | 0.20× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IIIN
| Welded Wire Reinforcement | $108.4M | 68% |
| PC Strand | $51.6M | 32% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
